Guinea Pig Complement (Fresh Frozen)
no-image-default.jpg
Datasheet is currently unavailable. Try again or CONTACT US
Datasheet

Guinea Pig Complement (Fresh Frozen)

C300-0500 C300-0010 C300-0050 C300-0100
500 mL 10 mL 50 mL 100 mL
Cellular Assay, ELISA, FC
Guinea Pig
Have a Question? Ask a Specialist
Please call for pricing
$345.00 /Per Item
$804.00 /Per Item
$1,273.00 /Per Item
500 mL $0.00
10 mL $345.00
50 mL $804.00
100 mL $1,273.00
Availability: Ships next business day Availability: Ships next business day Availability: Ships in approximately 14 days Availability: Ships next business day
Shipping info:

$50.00 to US & Canada for most products. Final costs are calculated at checkout.

Description

Background

Special processing techniques are used to yield products with high complement activity and low background cytotoxicity. Guinea Pig Complement is suitable for CFT and SRH.

Application Note

pH: normal Immunoelectrophoresis: normal Hemoglobin: normal IgG Concentration: normal

GUINEA PIG COMPLEMENT (fresh frozen) - C300-0010
Complement system, tissue macrophages, blood monocytes, protease C3-convertase, mannose-binding lectin pathway, C3, C3a, C3b, C5a, C5b, C6, C7, C8, and polymeric C9, cascade cleavage and activation events, recruit inflammatory cells, anaphylatoxin
Cellular Assay, ELISA, FC
Guinea Pig
Complement
Mixed
Guinea Pig - Mixed
Non-sterile
Fresh Frozen
72 mg/ml by Refractometry
None
None
None
Dry Ice
Store Guinea Pig Complement at -70° C prior to opening. Aliquot contents and freeze at -70° C or below. Use aseptic technique to maintain sterility when opening product. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. COMPLEMENT IS A TEMPERATURE SENSITIVE PRODUCT. IMPROPER STORAGE WILL INACTIVATE COMPLEMENT ACTIVITY.
Expiration date is one (1) year from date of opening.
Zhu, Y et al. Involvement of MST1/mTORC1/STAT1 activity in the regulation of B-cell receptor signalling by chemokine receptor 2. Clinical and Translational Medicine (2022)
Applications
B-Cell Purification
Yang L et al. CCL2 regulation of MST1-mTOR-STAT1 signaling axis controls BCR signaling and B-cell differentiation. Cell Death Differ. (2021)
Applications
Other
Li N, Jiang P, Chen A, et al. CX3CR1 positively regulates BCR signaling coupled with cell metabolism via negatively controlling actin remodeling. Cell Mol Life Sci. (2020)
Applications
Other
Jing Y. et. al. STING couples with PI3K to regulate actin reorganization during BCR activation. IMMUNOLOGY (2020)
Applications
Other
Yang JS et al. IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity. PLoS One. (2019)
Applications
Other
Hosseini SM et al. Transcriptome profiling of bovine inner cell mass and trophectoderm derived from in vivo generated blastocysts. BMC Dev Biol. (2015)
Applications
Inner Cell Mass (ICM)
Chen WH et al. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae. Clin Vaccine Immunol. (2014)
Applications
E, EIA
Zhang J et al. Development and characterization of an infectious cDNA clone of the modified live virus vaccine strain of equine arteritis virus. Clin Vaccine Immunol. (2012)
Applications
Other
Ozawa M et al. Importance of culture conditions during the morula-to-blastocyst period on capacity of inner cell-mass cells of bovine blastocysts for establishment of self-renewing pluripotent cells. Theriogenology. (2012)
Applications
Other
LaFleur RL et al. One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin. Clin Vaccine Immunol. (2010)
Applications
FC, FACS, FLOW
Yang JS et al. A duplex vibriocidal assay to simultaneously measure bactericidal antibody titers against Vibrio cholerae O1 Inaba and Ogawa serotypes. J Microbiol Methods. (2009)
Applications
Undefined
Yang JS et al. A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses. J Microbiol Methods. (2007)
Applications
Undefined
Whitaker-Menezes D et al. An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression. Biol Blood Marrow Transplant. (2003)
Applications
Other
Lynch JM et al. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun. (2003)
Applications
Other
Jones SC et al. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+ 25+ T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. (2003)
Applications
Other
Patterson AE et al. Infusion of select leukemia-reactive TCR Vbeta+ T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. (2001)
Applications
Other
Schnaper HW wt al. Identification and initial characterization of concanavalin A- and interferon-induced human suppressor factors: evidence for a human equivalent of murine soluble immune response suppressor (SIRS). J Immunol. (1984)
Applications
Undefined
Rittenberg MB et al. In vitro initiated secondary anti-hapten response. 3. Separable roles of hapten and carrier in immune paralysis. Immunohistochemistry. (1972)
Applications
Undefined

Invalid lot number

If you need help finding your CofA, contact us

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.